Discovery of (2-fluoro-benzyl)-(2-methyl-2-phenethyl-2h-chromen-6-yl)-amine (KRH-102140) as an orally active 5-lipoxygenase inhibitor with activity in murine inflammation models

Pharmacology

Volumn 87, Issue 1-2, 2011, Pages 49-55

  Cho, Young Sik ^a,b   Song, Jin Sook ^a   Huh, Jun Young ^a   Kim, Chi Hyun ^a   Gong, Young Dae ^a,c   Cheon, Hyae Gyeong ^a,d  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Dongguk University   (South Korea)

^d Gachon University   (South Korea)

Author keywords

5 Lipoxygenase; Air pouch; Ear edema; KRH 102140; Leukotriene B4

Indexed keywords

(2 FLUORO BENZYL) (2 METHYL 2 PHENETHYL 2H CHROMEN 6 YL)AMINE; ANTIINFLAMMATORY AGENT; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; KRH 102140; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; METHEMOGLOBIN; MYELOPEROXIDASE; UNCLASSIFIED DRUG; ZYMOSAN;

AIR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; EAR EDEMA; EDEMA; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKEMIA CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; BENZOPYRANS; BENZYLAMINES; CELL LINE; DRUG DISCOVERY; EDEMA; HALF-LIFE; INFLAMMATION; LEUKOCYTES; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED ICR; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS;

EID: 78650879821     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322642     Document Type: Article

References (23)

1. Radmark O: 5-Lipoxygenase-derived leukotrienes: mediators also of atherosclerotic inflammation. Arterioscler Thromb Vasc Biol 2003; 23: 1140-1142. (Pubitemid 36871266)
2. Sampson AP: The leukotrienes: mediators of chronic inflammation in asthma. Clin Exp Allergy 1996; 26: 995-1004. (Pubitemid 26306709)
3. van Deventer SJH: Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 2002; 50: 47-53.
4. Brooks, CDW, Summers JB: Modulators of leukotriene biosynthesis and receptor activation. J Med Chem 1996; 39: 2629-2654. (Pubitemid 26240330)
5. Westcott JY, Smith HR, Wenzel SE, Larsen GL, Thomas RB, Felsien D, et al: Urinary leukotriene E 4 in patients with asthma: effect of airways reactivity and sodium cromoglycate. Am Rev Respir Dis 1991; 143: 1322-1328.
6. Brain SD, Camp RD, Dowd PM, Black AK, Woollard PM, Mallet AI, et al: Psoriasis and leukotriene B 4 . Lancet 1982;ii:762-763.
7. Thorsen S, Fogh K, Broby-Johansen U, Søndergaard J: Leukotriene B 4 in atopic dermatitis: increased skin levels and altered sensitivity of peripheral blood T-cells. Allergy 1990; 45: 457-463. (Pubitemid 20286262)
8. 1993; 119: 1059-1066. (Pubitemid 23359918)
9. Falgueyret JP, Hutchinson JH, Riendeau D: Criteria for the identification of non-redox inhibitors of 5-lipoxygenase. Biochem Pharmacol 1993; 45: 978-981. (Pubitemid 23071451)
10. Lau CK, Bélanger PC, Dufresne C, Scheigetz J, Therieu M, Fitzsimmons B: Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2- phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase. J Med Chem 1992; 35: 1299-1318.
11. Gong YD, Cheon HG, Jeon MK, Cho YS, Hwang JY, Choi HS, et al: 6-Alkylamino- 2,2′-disubstituted-7,8-disubstituted-2H-1- benzopyran derivatives as 5-lipoxygenase inhibitor. Korea pat. No. 10-0602191, US pat. No. 7368575.
12. Waslidge NB, Hayes DJ: A colorimetric method for the determination of lipoxygenase activity suitable for use in a highthroughput assay format. Anal Biochem 1995; 231: 354-358.
13. Cho YS, Kim HS, Kim CH, Cheon HG: Application of the ferrous oxidation-xylenol orange assay for the screening of 5-lipoxygenase inhibitors. Anal Biochem 2006; 351: 62-68.
14. Suzuki H, Ueda T, Juranek I, Yamamoto S, Katoh T, Node M, Suzuki T: Hinokitiol, a selective inhibitor of the platelet-type isozyme of arachidonate 12-lipoxygenase. Biochem Biophys Res Commun 2000; 275: 885-889.
15. Walther M, Holzhütter HG, Kuban RJ, Wiesner R, Rathmann J, Kühn H: The inhibition of mammalian 15-lipoxygenases by the antiinflammatory drug ebselen: dual-type mechanism involving covalent linkage and alteration of the iron ligand sphere. Mol Pharmacol 1999; 56: 196-203. (Pubitemid 29309829)
16. Bradley PP, Priebat DA, Christensen RD, Rothstein G: Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78: 206-209. (Pubitemid 12171880)
17. Posadas I, Terencio MC, Guillén I, Ferrándiz ML, Coloma J, Payá M, et al: Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the timecourse of murine inflammation. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 98-106. (Pubitemid 30064661)
18. Fox CL Jr, Ottenberg R: Acute hemolytic anemia from the sulfonamides. J Clin Invest 1941; 20: 593-602.
19. Lanas A, Hunt R: Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. Ann Med 2006; 38: 415-428. (Pubitemid 44484879)
20. Dajani EZ, Islam K: Cardiovascular and gastrointestinal toxicity of selective cyclooxygenase- 2 inhibitors in man. J Physiol Pharmacol 2008; 59(suppl 2):117-133.
21. Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues D: Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003; 31: 1352-1360. (Pubitemid 37310324)
22. Chasteen ND, Grady JK, Skorey KI, Neden KJ, Riendeau D, Percival MD: Characterization of the non-heme iron center of human 5-lipoxygenase by electron paramagnetic resonance, fluorescence and ultraviolet-visible spectroscopy: redox cycling between ferrous and ferric states. Biochemistry 1993; 32: 9763-9771. (Pubitemid 23296823)
23. Werz O, Szellas D, Henseler M, Steinhiber D: Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol 1998; 54: 445-451. (Pubitemid 28368835)